Gursoy Alptekin, Ertugrul Derun Taner, Sahin Mustafa, Tutuncu Neslihan Bascil, Demirer Asli Nar, Demirag Nilgun Guvener
Department of Endocrinology and Metabolism, Baskent University Faculty of Medicine, 5 Cadde No 48, 06490 Bahcelievler, Ankara, Turkey.
Clin Endocrinol (Oxf). 2007 May;66(5):691-4. doi: 10.1111/j.1365-2265.2007.02802.x. Epub 2007 Mar 23.
Pain is one of the few drawbacks of fine-needle aspiration biopsy (FNAB) in patients with nodular thyroid disease (NTD). Lidocaine/prilocaine cream, an eutectic mixture of local anaesthetics (EMLA), is a frequently used topical anaesthetic. Despite its well-documented efficacy for the relief of pain associated with other cutaneous procedures that involve needle insertion, the analgesic role of EMLA has not been previously reported in patients with NTD who are undergoing FNAB. The aim of this study was to determine the analgesic efficacy of EMLA for FNAB-associated pain in patients with NTD.
Double-blind, placebo-controlled clinical trial.
The study was conducted at a thyroid outpatient clinic. We studied 99 patients with NTD.
Patients with NTD were allocated to receive either 2.5 g of EMLA (n = 50) or placebo (n = 49) 60 min before ultrasonographically guided FNAB. A series of four biopsies of each nodule was performed. Patients rated pain associated with the procedure according to a 100-mm visual analogue scale (VAS), an 11-point numeric rating scale (NRS), and 4-category verbal rating scale (VRS).
When the EMLA group was compared with the placebo group, there were no significant differences with respect to age, sex, thyroid volume, nodule size or nodule site. Significant differences were noted in the pain ratings of the two groups according to all three pain scales. When the effectiveness of EMLA was compared with that of placebo, the mean VAS score was 25.0 +/- 22.3 mm vs. 40.0 +/- 30.5 mm (P = 0.006) and the mean NRS score was 2.9 +/- 2.3 points vs. 4.0 +/- 2.6 points (P = 0.02). The absolute numbers according to VRS score in each group was also significantly different (P = 0.01). Although our sample size was small, the data suggest that FNAB-associated pain was sex-related and that women were significantly more sensitive than were men (P = 0.003 for VAS score and P = 0.001 for NRS score). No adverse effects from the use of EMLA were reported.
To our knowledge, this is the first study demonstrating that a topical anaesthetic, EMLA, provides an effective and noninvasive analgesia during the FNAB of NTD.
疼痛是甲状腺结节性疾病(NTD)患者进行细针穿刺活检(FNAB)的少数缺点之一。利多卡因/丙胺卡因乳膏,一种局部麻醉剂的共熔混合物(EMLA),是一种常用的局部麻醉剂。尽管其对缓解与其他涉及针头插入的皮肤操作相关的疼痛的疗效已有充分记录,但EMLA在接受FNAB的NTD患者中的镇痛作用此前尚未见报道。本研究的目的是确定EMLA对NTD患者FNAB相关疼痛的镇痛效果。
双盲、安慰剂对照临床试验。
研究在甲状腺门诊进行。我们研究了99例NTD患者。
NTD患者在超声引导下FNAB前60分钟被分配接受2.5 g EMLA(n = 50)或安慰剂(n = 49)。对每个结节进行一系列四次活检。患者根据100毫米视觉模拟量表(VAS)、11点数字评定量表(NRS)和4级语言评定量表(VRS)对与该操作相关的疼痛进行评分。
将EMLA组与安慰剂组进行比较,在年龄、性别、甲状腺体积、结节大小或结节部位方面无显著差异。根据所有三种疼痛量表,两组的疼痛评分存在显著差异。将EMLA与安慰剂的有效性进行比较时,平均VAS评分为25.0±22.3毫米 vs. 40.0±30.5毫米(P = 0.006),平均NRS评分为2.9±2.3分 vs. 4.0±2.6分(P = 0.02)。每组根据VRS评分的绝对数字也有显著差异(P = 0.01)。尽管我们的样本量较小,但数据表明FNAB相关疼痛与性别有关,女性比男性明显更敏感(VAS评分P = 0.003,NRS评分P = 0.001)。未报告使用EMLA的不良反应。
据我们所知,这是第一项证明局部麻醉剂EMLA在NTD患者FNAB期间提供有效且无创镇痛作用的研究。